# China NMPA Drug Inspection - Beijing Shengshilong Pharmaceutical Co., Ltd. - yam

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/beijing-shengshilong-pharmaceutical-co-ltd/cb933c4b-706c-432c-aa0f-650b7801ab78/
Source feed: China

> China NMPA drug inspection for Beijing Shengshilong Pharmaceutical Co., Ltd. published June 22, 2018. Drug: yam. On June 22, 2018, the National Medical Products Administration (NMPA) of China issued an announcement detailing the non-

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 46 of 2018 from the National Medical Products Administration regarding 10 batches of drugs that did not meet the requirements.
- Company Name: Beijing Shengshilong Pharmaceutical Co., Ltd.
- Publication Date: 2018-06-22
- Drug Name: yam
- Inspection Finding: Total ash content does not meet regulations
- Action Taken: Relevant drug regulatory authorities have taken control measures such as sealing and seizing, requiring enterprises to suspend sales and use, recall products and make rectifications; relevant provincial drug regulatory authorities will investigate and prosecute illegal acts of producing and selling counterfeit and substandard drugs in accordance with the "Drug Administration Law of the People's Republic of China" and make the results public.
- Summary: On June 22, 2018, the National Medical Products Administration (NMPA) of China issued an announcement detailing the non-compliance of 10 batches of drugs produced by nine enterprises. Following tests by various provincial drug control institutes, companies such as Tonghua Xinghua Pharmaceutical Co., Ltd., Yantai Juxian Pharmaceutical Co., Ltd., and Bozhou Jingwan Traditional Chinese Medicine Pieces Factory were identified for significant quality control deficiencies. Main issues included substandard active ingredient content, inadequate dissolution rates, inconsistent fill weight uniformity, and unacceptable levels of ash content or appearance defects in products like Acanthopanax senticosus granules, Metoprolol tartrate tablets, and traditional Chinese medicine pieces.

In response to these findings, regulatory authorities implemented immediate control measures, including sealing and seizing the affected products. The implicated companies were mandated to cease sales, recall the non-compliant drugs, and rectify the identified issues. Operating under the Drug Administration Law of the People's Republic of China, the NMPA directed provincial drug regulatory bodies to conduct thorough investigations into the illegal activities of these manufacturers. These investigations were required to be completed, and their results publicly disclosed, within three months, ensuring accountability and adherence to national drug quality standards.

Company: https://www.globalkeysolutions.net/companies/beijing-shengshilong-pharmaceutical-co-ltd/abd85ccb-d753-4e45-8550-04fc279f00aa/